Sustainable treatment of glaucoma patients with cardiovascular diseases
https://doi.org/10.21516/2072-0076-2020-13-3-103-107
Abstract
As life expectancy increases, the incidence of glaucoma is expected to rise worldwide. The review presents data on the comorbidity and polypharmacy of old and senile patients with glaucoma. Such patients also often have polypathia: on average, they have 6.3±0.6 concomitant somatic diseases. Approximately one in five glaucoma patients receives both a systemic and local beta-blocker (ВВ). Parallel use of local and systemic drugs in glaucoma patients is likely to cause drug interaction, increase side effects and contribute to an earlier onset of the tachyphylaxis. The selectivity of oral and local ВВ is one of the factors contributing to the prediction of their additive effect. The data on the expediency of prescribing brimonidine as the first-choice drug for glaucoma and hypertension patients who were previously prescribed systemic ВВ are presented.
About the Authors
L. V. Yakubova
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Liya V. Yakubova — Cand. of Med. Sci., senior researcher, department of glaucoma.
14/19, Sadovaya Chernogryazskaya St., Moscow, 105062
S. M. Kosakyan
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Srbui M. Kosakyan — Cand. of Med. Sci., ophthalmologist, department of glaucoma.
14/19, Sadovaya Chernogryazskaya St., Moscow, 105062
L. V. Vasilenkova
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Lubov V. Vasilenkova — Cand. of Med. Sci., researcher, department of glaucoma.
14/19, Sadovaya Chernogryazskaya St., Moscow, 105062
References
1. Kiseleva O.A., Kosakyan S.M., Yakubova L.V., Vasilenkova L.V. Interaction of antiglaucomatous drugs in patients with chronic concomitant diseases. Clinical ophthalmology. 2016; 16 (2): 16–9 (in Russian).
2. Heijl A., Leske M.C., Bengtsson B., et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 2002; 120 (10): 1268–79. doi: 10.1001/archopht.120.10.1268
3. Neroev V.V., Kiseleva O.A., Bessmertny A.M. Main results of a multicenter study of epidemiological features of primary open angle glaucoma in the Russian Federation. Russian ophthalmological journal. 2013; 3: 4–7 (in Russian).
4. Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 2002; 120 (6): 701–13. doi: 10.1001/archopht.120.6.701
5. Kharkоv E.I., Davydov E.L., Shulmin A.V. Elderly patient and arterial hypertension: features of course and therapy (Message I). Siberian medical review. 2010; 3 (63): 3–8 (in Russian).
6. Onishchenko A.L., Kolbasko A.V., Zakharova A.V., Onishchenko E.G., Zhilina N.M. Ophthalmohypotensive effect of systemic use of beta-blockers in primary glaucoma and arterial hypertension. Vestnik oftal’mologii. 2017; 133 (2): 46–50 (in Russian). doi:10.17116/oftalma2017133246-50
7. Makogon S.I., Makogon A.S. The features of comorbidity in primary openangle glaucoma patients in different age groups. The Bulletin of Contemporary Clinical Medicine. 2016; 9 (6): 61–6 (in Russian).
8. Stein J.D., Newman-Gasey P.A., Musch D.C., et al. Association between the use of glaucoma medications and mortality. Arch. Ophthalmol. 2010; 128 (2): 235–40. doi: 10.1001/archophthalmol.2009.378
9. Masnoon N., Shakib S., Kalisch-Ellett L., et al. What is polypharmacy? A systematic review of definitions. BMC Geriatrics. 2017; 17 (1): 230. doi: 10.1186/s12877-017-0621-2
10. Diggory P., Franks W. Medical treatment of glaucoma — a reappraisal of the risks. Br. J. Ophthalmol. 1996; 80: 85–9. doi: 10.1136/bjo.80.1.85
11. Pereira K.G., Peres М.А., Iop D., et al. Polypharmacy among the elderly: a population-based study. Rev. Bras. Epidemiol. 2017; 20 (2): 335–44. doi: 10.1590/1980-5497201700020013
12. Gottfredsdottir M.S., Allingham R.R., Shields M.B. Physicians’ guide to interactions between glaucoma and systemic medications. J. Glaucoma. 1997; 6: 377– 83.
13. Huber M., Kölzsch M., Stahlmann R., et al. Ophthalmic drugs as part of polypharmacy in nursing home residents with glaucoma. Drugs Aging. 2013; 30 (1): 31–8. doi: 10.1007/s40266-012-0036-x
14. Goldberg I., Adena M.A. Co-prescribing of topical and systemic beta-blockers in patients with glaucoma: a quality use of medicine issue in Australian practice. Clin. Exp. Ophthalmol. 2007; 35 (8): 700–5. doi.org/10.1111/j.1442-9071.2007.01573.x
15. Caughey G.E., Roughead E.E., Shakib S., et al. Co-morbidity and potential treatment conflicts in elderly heart failure patients: a retrospective, crosssectional study of administrative claims data. Drugs Aging. 2011 Jul 1; 28 (7): 575–81. doi: 10.2165/11591090-000000000-00000
16. Roughead E.E., Kalisch L.M., Pratt N.L., et al. Managing glaucoma in those with co-morbidity: not as easy as it seems. Ophthalmic Epidemiol. 2012; 19 (2): 74–82. doi: 10.3109/09286586.2011.638743
17. Gurevich M.A. Chronic heart failure treatment in elderly patients. Russian Journal of Cardiology. 2008; (4): 93–100 (in Russian). https://doi.org/10.15829/1560-4071-2008-4-93-100
18. Lee A.J., Wang J.J., Kifley A., et al. Open-angle glaucoma and cardiovascular mortality (The Blue Mountains Eye Study). Ophthalmology. 2006; 113: 1069–76. doi.org/10.3109/09286586.2011.638743
19. Onishhenko A.L., Kolbasko A.V., Zhilina I.N., Isakov I.N., Vlasenko A.E. Life expectancy of patients with primary glaucoma, residents of a large industrial city of Siberia. Vestnik oftal'mologii. 2014; 2: 32–6 (in Russian).
20. Nedogoda S.V., Ledjaeva A.A., Chumachok E.G., et al. Beta-adrenolytic nebivolol nebivolol for the treatment of arterial hypertension in real clinical practice. Spravochnik poliklinicheskogo vracha. 2012; 1: 10–4 (in Russian).
21. Kiseleva O.A., Yakubova L.V., Bessmertny A.M. Beta-blockers in the treatment of glaucoma: history and prospects. Effective pharmacotherapy. Ophthalmology. 2018; 2: 4–17 (in Russian).
22. Mäenpää J., Pelkonen O. Cardiac safety of ophthalmic timolol. Expert Opin. Drug Saf.; 2016: 15 (11): 1549–61. doi.org/10.1080/14740338.2016.1225718
23. Zimmerman T.J., Kooner K.S., Kandarakis A.S., et al. Improving the therapeutic index of topically applied ocular drugs. Arch. Ophthalmol. 1984; 102 (7): 601–4. doi: 10.1001/archopht.1984.01040030429017
24. Hoste A.M. Beta-Blockers. In: Shaarawy T.M., Sherwood M.B., Hitchings R.A., Crowston J.G., eds. Glaucoma — Medical Diagnosis & Therapy. London: Elsevier; 2014: 548–58.
25. De Moraes C.G., Cioffi G.A., Weinreb R.N., et al. New recommendations for the treatment of systemic hypertension and their potential implications for glaucoma management. Journal of Glaucoma. 2018; 27 (7): 567–71. doi.org/10.1097/IJG.0000000000000981
26. Chauhan J.R., Mishra Y.C., Khilnani K. A clinical study of effect of oral atenolol on normal intraocular pressure and systemic blood pressure. Indian J. Ophthalmol. 1989; 37: 179–81. PMID: 2700474
27. Elliot M.J., Cullen P.M., Phillips C.I. Ocular hypotensive effect of atenolol (Tenormin, I.c.i.) A new beta-adrenergic blocker. Br. J. Ophthalmol. 1975; 59 (6): 296–300. doi: 10.1136/bjo.59.6.296
28. Macdonald M.J., Cullen P.M., Phillips C.I. Atenolol versus propranolol. A comparison of ocular hypotensive effect of an oral dose. Br. J. Ophthalmol. 1976; 60 (11): 789–91. doi: 10.1136/bjo.60.11.789
29. Szumny D., Szeląg A. The influence of new beta-adrenolytics nebivolol and carvedilol on intraocular pressure and iris blood flow in rabbits. Graefe's Arch. Clin. and Exp. Ophthalmol. 2014; 252 (6): 917–23. doi: 10.1007/s00417-014-2623-5
30. Wettrell K., Pandolfi M. Effect on oral administration of various beta-blocking agents on the intraocular pressure in healthy volunteers. Exp. Eye Res. 1975; 21 (5): 451–6. doi: 10.1016/0014-4835(75)90126-8
31. Ohrström A., Pandolfi M. Long-term treatment of glaucoma with systemic propranolol. 1978. Am. J. Ophthalmol. 1978; 86: 340–4.
32. Stenkula E., Wettrell K. A Dose-response study of oral atenolol administered once daily in patients with raised intra-ocular pressure. Graefe's Arch. Clin. Exp. Ophthalmol. 1982; 218: 96–8. doi: 10.1007/BF02153719
33. Phillips C.I., Howitt G., Rowlands D.J. Propranolol as ocular hypotensive agent. Brit. J. Ophthal. 1967; 51: 222–6.
34. Onishchenko A.L., Kolbasko A.V., Safronova M.A., et al. The study of the ophthalomohypotensive effectiveness of metoprolol when administered parenterally in the experiment. Vestnik oftal’mologii. 2015; 131 (4): 79–82 (in Russian).
35. Batchelor E.D., O’Day D.M., Shand D.G., et al. Interaction of topical and oral timolol in glaucoma. Ophthalmology. 1979; 86: 60–5. doi: 10.1016/S0161-6420(79)35544-0
36. Blondeau P., Cote M., Tetrault L. Effect of timolol eye drops in subjects receiving systemic propanolol therapy. Can. J. Ophthalmol. 1983; 18: 18–21.
37. Williamson J., Young J.D.H., Atta H., et al. Comparative efficacy of orally and topically administered beta-blockers for chronic simple glaucoma. Br. J. Ophthalmol. 1985; 69: 41–5. doi: 10.1136/bjo.69.1.41
38. Gross F.J., Schuman J.S. Reduced ocular hypotensive effect of topical β-blockers in glaucoma patients receiving oral β-blockers. J. Glaucoma. 1992; 1 (3): 174–7.
39. Schuman J.S. Effects of systemic -blocker therapy on the efficacy and safety of topical brimonidine and timolol. Ophthalmology. 2000 Jun; 107 (6): 1171–7. doi: 10.1016/s0161-6420(00)00081-6
40. Schuman J.S., Horwitz B., Choplin N.T., et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter trial. Arch. Ophthalmol. 1997; 115: 847–52. doi: 10.1001/archopht.1997.01100160017002
41. Le Blanc R P. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2 % and timolol 0.5 % given twice daily in patients with glaucoma or ocular hypertension. Ophthalmology. 1998; 105: 1960–7. doi: 10.1016/s0161-6420(98)91048-x
42. Weinreb R.N., Araie M., Susanna R., et al., eds. Medical treatment of glaucoma.
Review
For citations:
Yakubova L.V., Kosakyan S.M., Vasilenkova L.V. Sustainable treatment of glaucoma patients with cardiovascular diseases. Russian Ophthalmological Journal. 2020;13(3):103-107. (In Russ.) https://doi.org/10.21516/2072-0076-2020-13-3-103-107
Views:
741
Email this article 